<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-0319</journal-id>
<journal-title><![CDATA[Medicas UIS]]></journal-title>
<abbrev-journal-title><![CDATA[Medicas UIS]]></abbrev-journal-title>
<issn>0121-0319</issn>
<publisher>
<publisher-name><![CDATA[Universidad Industrial de Santander]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-03192017000100057</article-id>
<article-id pub-id-type="doi">10.18273/revmed.v30n1-2017005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Metformina: más allá del control glucémico]]></article-title>
<article-title xml:lang="en"><![CDATA[Metformin: beyond the glycemic target]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morantes-Caballero*]]></surname>
<given-names><![CDATA[Jairo A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Londoño-Zapata*]]></surname>
<given-names><![CDATA[Gabriel A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rubio-Rivera*]]></surname>
<given-names><![CDATA[Manuela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinilla-Roa**]]></surname>
<given-names><![CDATA[Análida Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[Bogotá Distrito Capital]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[Bogotá Distrito Capital]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<volume>30</volume>
<numero>1</numero>
<fpage>57</fpage>
<lpage>71</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-03192017000100057&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-03192017000100057&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-03192017000100057&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  la metformina es una biguanida que disminuye gluconeogénesis e incrementa la recaptación de glucosa en los músculos, sin embargo, más allá del glucémico se han documentado beneficios adicionales como la disminución de complicaciones crónicas derivadas de la hiperglucemia, entre ellas las cardiovasculares y del síndrome metabólico per se.  Objetivo:  identificar los efectos de la metformina diferentes al control control glucémico en población con diabetes mellitus, con el fin de contribuir a difundir el conocimiento.  Materiales y método: tres revisores independientes realizaron la búsqueda en distintas bases de datos entre ellas Pubmed y ScienceDirect, utilizando los términos Metfomin AND Cardiovascular disease AND inflamatory response AND Hyperlipidemia, Biguanides, Diabetes Mellitus, Diabetes complications, Obesity, Vascular diseases AND Cancer; y Metfomina y enfermedad cardiovascular, metformina y cáncer se seleccionaron los artículos desde el año 2010, encontrando 13 828 artículos, de los cuales se incluyeron 144.  Conclusión: más allá del control glucémico, la metformina, modifica la &#8220;memoria metabólica&#8221;, reduce mediadores inflamatorios y el grosor de pared arterial, disminuye factores trombóticos y reduce la prevalencia de falla cardiaca logrando impactar la morbimortalidad y mediante cambios moleculares o genéticos, tiene potencial uso como anticancerígeno. El clínico debe conocer estos efectos para favorecer su pronto inicio en los casos indicados. MÉD.UIS. 2017;30(1):57-71.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: the metformin is a biguanide which main action is to decrease hepatic glucose output, primarily by decreasing gluconeogenesis, and increase glucose uptake by muscles. However, beyond the glycemic target, additional benefits have been documented like a decrease in chronic complications to hyperglycemia, including cardiovascular comorbility and metabolic syndrome.  Objetive: to identify effects of metformin other than glycemic control in patients with diabetes mellitus in order to help disseminate knowledge.  Materials and methods: three independent reviewers searched in different databases of PubMed and ScienceDirect using the DeCS and MeSH terms: Metfomin AND Cardiovascular disease AND inflamatory response AND Hyperlipidemia, Biguanides, Diabetes Mellitus, Diabetes complications,Obesity, Vascular diseases AND Cancer, selecting the items since 2010 year and prior to warrant mention. Search based publications that were considered most relevant and, additionally, a manual search of the referenced articles in publications retrieved in the initial search was conducted, 13 828 articles were found but 144 were included finally.  Conclusion: beyond glycemic control, Metformin, modifies the &#8220;metabolic memory&#8221;, reduces inflammatory mediators and thickness of arterial wall, decreases thrombotic factors and reduces the prevalence of heart failure making an impact morbidity and mortality and because of molecular or genetic changes, it has potential use as anticarcinogenic. The physicians should know it to facilitate the early administration of this medication when it is indicated. MÉD.UIS. 2017;30(1):57-71.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Metformina]]></kwd>
<kwd lng="es"><![CDATA[Diabetes Mellitus]]></kwd>
<kwd lng="es"><![CDATA[Proteínas Quinasas Activada por AMP]]></kwd>
<kwd lng="es"><![CDATA[Obesidad]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades Vasculares]]></kwd>
<kwd lng="es"><![CDATA[Neoplasias.]]></kwd>
<kwd lng="en"><![CDATA[Metformin]]></kwd>
<kwd lng="en"><![CDATA[Diabetes Mellitus]]></kwd>
<kwd lng="en"><![CDATA[AMP-Activated Protein Kinases]]></kwd>
<kwd lng="en"><![CDATA[Neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Obesity]]></kwd>
<kwd lng="en"><![CDATA[Vascular Diseases.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>Centers for Disease Control and Prevention</collab>
<source><![CDATA[National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta,]]></source>
<year>2014</year>
<publisher-loc><![CDATA[GA ]]></publisher-loc>
<publisher-name><![CDATA[US Department of Health and Human Services]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mortality rates and the causes of death related to diabetes mellitus in Shanghai Songjiang District an 11-year retrospective analysis of death certificates]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Weaver]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Endocr Disord]]></source>
<year>2015</year>
<volume>15</volume>
<page-range>45</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of intensive glucose lowering in type 2 diabetes]]></article-title>
<collab>Action to Control Cardiovascular Risk in Diabetes Study G.Gerstein HC.Miller ME.Byington RP.Goff DC.Jr.Bigger JT</collab>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>358</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2545-59</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A prescription survey in diabetes assessing metformin use in a tertiary care hospital in Eastern India]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nandy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mandal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Banerjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharmacol Pharmacother]]></source>
<year>2012</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>273-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Approaches to Glycemic Treatment]]></article-title>
<collab>American Diabetes Association</collab>
<source><![CDATA[Diabetes Care]]></source>
<year>2016</year>
<volume>39</volume>
<page-range>S52-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cardiovascular impact of drugs used in the treatment of diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Triggle]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Ther Adv Chronic Dis]]></source>
<year>2014</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>245-68</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Standards of medical care in diabetes]]></article-title>
<collab>American Diabetes Association</collab>
<source><![CDATA[Diabetes Care]]></source>
<year>2014</year>
<volume>37</volume>
<page-range>S14-80</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Konrad]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Datz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Engelsberger]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Grulich-Henn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hoertenhuber]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Knauth]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Diabetes]]></source>
<year>2014</year>
<volume>16</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>529-37</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glueck]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fontaine]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Subbiah]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Illig]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Metabolism]]></source>
<year>2001</year>
<volume>50</volume>
<page-range>856-61</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The early treatment of type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pratley]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Med]]></source>
<year>2013</year>
<volume>126</volume>
<page-range>S2-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metabolic effects of metformin in non-insulin-dependent diabetes mellitus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stumvoll]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nurjhan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Perriello]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dailey]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gerich]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>1995</year>
<volume>333</volume>
<page-range>550-4</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin--mode of action and clinical implications for diabetes and cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pernicova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Korbonits]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Endocrinol]]></source>
<year>2014</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>143-56</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Target of Metformin in Type 2 Diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<page-range>1547-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Control of gluconeogenesis by metformin does redox trump energy charge?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baur]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Birnbaum]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell Metab]]></source>
<year>2014</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>197-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanism by which metformin reduces glucose production in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hundal]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Krssak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dufour]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Laurent]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lebon]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Chandramouli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2000</year>
<volume>49</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2063-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Molecular mechanism of action of metformin Old or new insights?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rena]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Sakamoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2013</year>
<volume>56</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1898-906</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cellular and molecular mechanisms of metformin an overview]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viollet]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Guigas]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sanz Garcia]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Leclerc]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Foretz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andreelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Sci]]></source>
<year>2011</year>
<volume>122</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>253-70</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes Stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Thazhath]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Bound]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Horowitz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rayner]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2014</year>
<volume>106</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e3-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farilla]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hui]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bertolotto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bulotta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Di Mario]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocrinology]]></source>
<year>2002</year>
<volume>143</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>4397-408</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physiological role of incretins and its importance in type 2 diabetes mellitus]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Balladares]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vera]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bognanno]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Marin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Infor Med]]></source>
<year>2009</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>437-43</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Oral pharmacologic treatment of type 2 diabetes mellitus A clinical practice guideline from the american college of physicians]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qaseem]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Humphrey]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Sweet]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Starkey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shekelle]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>2012</year>
<volume>156</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>218-31</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparative effectiveness and safety of medications for type 2 diabetes An update including new drugs and 2-drug combinations]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Maruthur]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Segal]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Chatterjee]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>2011</year>
<volume>154</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>602-18</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Look AHEAD (Action for Health in Diabetes) design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Espeland]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Haffner]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Hubbard]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<source><![CDATA[Control Clin Trials;]]></source>
<year>2003</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>610-28</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romanelli]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nimbal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Palaniappan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2015</year>
<volume>108</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Haffner]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Heise]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Herman]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Holman]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>355</volume>
<page-range>2427-43</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group]]></article-title>
<collab>No authors</collab>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>352</volume>
<numero>9131</numero>
<issue>9131</issue>
<page-range>837-53</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus a randomized prospective 6-year study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohkubo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kishikawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Araki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Miyata]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Isami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Motoyoshi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Res Clin Pract;]]></source>
<year>1995</year>
<volume>28</volume>
<page-range>103-17</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Improving survival with metformin the evidence base today]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scarpello]]></surname>
<given-names><![CDATA[JHB]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Metab]]></source>
<year>2003</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>6S36-43</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Held]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hjemdahl]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Bjorkander]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Forslund]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rehnqvist]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>2001</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>62-72</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Albuminuria is evident in the early stages of diabetes onset Results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tapp]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmet]]></surname>
<given-names><![CDATA[PZ]]></given-names>
</name>
<name>
<surname><![CDATA[Balkau]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chadban]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tonkin]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2004</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>792-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Singleton]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Intern Med]]></source>
<year>2004</year>
<volume>164</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1021-5</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome A cross-sectional analytic study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franciosi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pellegrini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sacco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Berardis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[MCE]]></given-names>
</name>
<name>
<surname><![CDATA[Strippoli]]></surname>
<given-names><![CDATA[GFM]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2007</year>
<volume>2</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>984-91</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YI]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[YE]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2001</year>
<volume>52</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>14552</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Group]]></surname>
<given-names><![CDATA[DPPR]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabet Med]]></source>
<year>2007</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>137-44</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Relation between fasting glucose and retinopathy for diagnosis of diabetes three population-based cross-sectional studies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[TY]]></given-names>
</name>
<name>
<surname><![CDATA[Liew]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tapp]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<volume>371</volume>
<numero>9614</numero>
<issue>9614</issue>
<page-range>736-43</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Stampfer]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Haffner]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Willett]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Manson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2002</year>
<volume>25</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1129-34</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levitzky]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Pencina]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of Impaired Fasting Glucose on Cardiovascular Disease The Framingham Heart Study]]></article-title>
<collab>D'Agostino RB.Meigs JB.Murabito JM.Vasan RS</collab>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2008</year>
<volume>51</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>264-70</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[ELM]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmet]]></surname>
<given-names><![CDATA[PZ]]></given-names>
</name>
<name>
<surname><![CDATA[Welborn]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Jolley]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Magliano]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dunstan]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>116</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>151-7</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knowler]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Barrett-Connor]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Hamman]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Lachin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med;]]></source>
<year>2002</year>
<volume>346</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>393-403</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Copeland]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Silverstein]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Prazar]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Raymer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shiffman]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatrics]]></source>
<year>2013</year>
<volume>131</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>364-82</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin resistance in nonobese patients with polycystic ovarian disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Judd]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>1983</year>
<volume>57</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>356-9</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin for the treatment of the polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nestler]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>358</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>47-54</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ehrmann]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenfield]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Cavaghan]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Imperial]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>1999</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>141-6</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome a retrospective analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Wickham III]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Nestler]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocr Pract]]></source>
<year>2007</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>373-9</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study]]></article-title>
<collab>Diabetes Prevention Program Research G</collab>
<source><![CDATA[Diabetes Care]]></source>
<year>2012</year>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>731-7</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Obesity related hyperinsulinaemia and hyperglycaemia and cancer development]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dossus]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kaaks]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Physiol Biochem]]></source>
<year>2009</year>
<volume>115</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>86-96</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adipokines and lipoproteins modulation by antihyperglycemic and hypolipidemic agents]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rizvi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sallam]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Montalto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abate]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Metab Syndr Relat Disord]]></source>
<year>2014</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leblanc]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of primary care-relevant treatments for obesity in adults a systematic evidence review for the U.S. Preventive Services Task Force]]></article-title>
<collab>O'Connor E.Whitlock EP.Patnode CD.Kapka T</collab>
<source><![CDATA[Ann Intern Med]]></source>
<year>2011</year>
<volume>155</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>434-47</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levri]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Slaymaker]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Last]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ference]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin as treatment for overweight and obese adults a systematic review]]></article-title>
<collab>D'Amico F</collab>
<source><![CDATA[Ann Fam Med]]></source>
<year>2005</year>
<volume>3</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>457-61</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese systematic review and meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nieuwenhuis-Ruifrok]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Kuchenbecker]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Hoek]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Middleton]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Hum Reprod Update]]></source>
<year>2009</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-68</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of two doses of metformin (2 5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruno]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
<name>
<surname><![CDATA[de Avila]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Neves]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Nardi]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Crespo]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Sobrinho]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<source><![CDATA[Fertil Steril]]></source>
<year>2007</year>
<volume>88</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>510-2</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonagh]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Selph]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ozpinar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Foley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA pediatr]]></source>
<year>2014</year>
<volume>168</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>178-84</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain a review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Macaluso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McHale]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dahmen]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Girrens]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[J Psychiatr Pract]]></source>
<year>2010</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>289-96</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hasnain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fredrickson]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Vieweg]]></surname>
<given-names><![CDATA[WV]]></given-names>
</name>
</person-group>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2011</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>715-21</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Importance of Controlling Diabetes Early-The Concept of Metabolic Memory, Legacy Effect and the Case for Early Insulinisation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Unnikrishnan]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Anjana]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mohan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[J Assoc Physicians India]]></source>
<year>2011</year>
<volume>59Supplement</volume>
<page-range>8-12</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Complications Trial/ Epidemiology of Diabetes I.Complications Research G Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus]]></article-title>
<collab>Writing Team for the Diabetes C</collab>
<source><![CDATA[JAMA]]></source>
<year>2002</year>
<volume>287</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2563-9</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chalmers]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>1993</year>
<volume>341</volume>
<numero>8856</numero>
<issue>8856</issue>
<page-range>1306-9</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The UK prospective diabetes study (UKPDS) clinical and therapeutic implications for type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Peacock]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Donnelly]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>1999</year>
<volume>48</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>643-8</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The beneficial effects of AMP-kinase activation against oxidative stress are associated with prevention of PPARalpha-cyclophilin D interaction in cardiomyocytes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barreto-Torres]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Soto Hernandez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Munoz]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Ramos]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Basnakian]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Physiol Heart Circ Physiol]]></source>
<year>2015</year>
<volume>308</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>749-58</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2012</year>
<volume>61</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>217-28</page-range></nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[La memoria metabólicainducida por la hiperglucemia el nuevo reto en la prevención de la enfermedad cardiovascular en la diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ceriello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2008</year>
<volume>8</volume>
<numero>C</numero>
<issue>C</issue>
<page-range>12-8</page-range></nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inflammation, glucose, and vascular cell damage the role of the pentose phosphate pathway]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peiro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Romacho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Azcutia]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Villalobos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bolanos]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiovasc Diabetol]]></source>
<year>2016</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>82</page-range></nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin effects on micro and macrovascular complications in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiovasc Drugs Ther]]></source>
<year>2008</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>215-24</page-range></nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[AMPK and vasculoprotection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ewart]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacol Ther]]></source>
<year>2011</year>
<volume>131</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>242-53</page-range></nlm-citation>
</ref>
<ref id="B65">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of oxidative stress and nitric oxide in atherothrombosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lubos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Handy]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Loscalzo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Front Biosci]]></source>
<year>2008</year>
<volume>13</volume>
<page-range>5323-44</page-range></nlm-citation>
</ref>
<ref id="B66">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of hyperglycemia in nitrotyrosine postprandial generation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ceriello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quagliaro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Catone]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pascon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Piazzola]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bais]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2002</year>
<volume>25</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1439-43</page-range></nlm-citation>
</ref>
<ref id="B67">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sirtuin 1 as a key player of 'metabolic memory' J Diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hashiramoto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kaku]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Investig]]></source>
<year>2013</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>34-6</page-range></nlm-citation>
</ref>
<ref id="B68">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[AMP-activated protein kinase, a metabolic master switch possible roles in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winder]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Hardie]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Physiol]]></source>
<year>1999</year>
<volume>277</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>E1-10</page-range></nlm-citation>
</ref>
<ref id="B69">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evidence for a cellular "memory" of hyperglycemic stress]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ceriello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ihnat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sismey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Kaltreider]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2005</year>
<volume>54</volume>
<page-range>218</page-range></nlm-citation>
</ref>
<ref id="B70">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin reduces TGF-beta1-induced extracellular matrix production in nasal polyp-derived fibroblasts]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Um]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<source><![CDATA[Otolaryngol Head Neck Surg]]></source>
<year>2014</year>
<volume>150</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>148-53</page-range></nlm-citation>
</ref>
<ref id="B71">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin Reduces Inflammation and Lung Fibrosis in a Bleomycin-Induced Lung Injury Model (LB505)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YW]]></given-names>
</name>
</person-group>
<source><![CDATA[The FASEB Journal]]></source>
<year>2014</year>
<volume>28</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>505</page-range></nlm-citation>
</ref>
<ref id="B72">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matsumoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sera]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Abe]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tominaga]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yeki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Miyake]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2004</year>
<volume>64</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>225-8</page-range></nlm-citation>
</ref>
<ref id="B73">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intimamedia thickness in subjects with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katakami]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yamasaki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hayaishi-Okano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ohtoshi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kaneto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Matsuhisa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2004</year>
<volume>47</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1906-13</page-range></nlm-citation>
</ref>
<ref id="B74">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Mamputu]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Wiernsperger]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Renier]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2005</year>
<volume>54</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2227-34</page-range></nlm-citation>
</ref>
<ref id="B75">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin stimulates ischemia-induced revascularization through an eNOS dependent pathway in the ischemic hindlimb mice model]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Shibata]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ouchi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sugimoto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Murohara]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Komori]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[J Vasc Surg]]></source>
<year>2015</year>
<volume>61</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>489-96</page-range></nlm-citation>
</ref>
<ref id="B76">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Jager]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kooy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schalkwijk]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term effects of metformin on endothelial function in type 2 diabetes a randomized controlled trial]]></article-title>
<collab>van der Kolk J.Lehert P.Bets D</collab>
<source><![CDATA[J Intern Med]]></source>
<year>2014</year>
<volume>275</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-70</page-range></nlm-citation>
</ref>
<ref id="B77">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin improves endothelial function in type 1 diabetic subjects a pilot, placebo-controlled randomized study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitocco]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zaccardi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tarzia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Milo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scavone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2013</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>427-31</page-range></nlm-citation>
</ref>
<ref id="B78">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus A single-blind study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tousoulis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Koniari]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Antoniades]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Miliou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Noutsou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolopoulou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Ther]]></source>
<year>2010</year>
<volume>32</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1720-8</page-range></nlm-citation>
</ref>
<ref id="B79">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin reduces vascular endothelial dysfunction caused by an acute glucose load in patients with hypertension]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[TX]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[JX]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chai]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[JX]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood Press]]></source>
<year>2013</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>106-13</page-range></nlm-citation>
</ref>
<ref id="B80">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El Messaoudi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schreuder]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Kengen]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Rongen]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of metformin on endothelial ischemia-reperfusion injury in humans in vivo a prospective randomized open, blinded-endpoint study]]></article-title>
<collab>van den Broek PH.Thijssen DH</collab>
<source><![CDATA[PLOS ONE]]></source>
<year>2014</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e96062</page-range></nlm-citation>
</ref>
<ref id="B81">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetylCoA and cholesterol in pancreatic tumor cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cantoria]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Boros]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Meuillet]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Metabolomics]]></source>
<year>2014</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>91-104</page-range></nlm-citation>
</ref>
<ref id="B82">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geerling]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Boon]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice]]></article-title>
<collab>van der Zon GC.van den Berg SA.van den Hoek AM.Lombes M</collab>
<source><![CDATA[Diabetes]]></source>
<year>2014</year>
<volume>63</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>880-91</page-range></nlm-citation>
</ref>
<ref id="B83">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of metformin and lipid emulsion on the circadian gene expression in muscle cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnea]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen-Yogev]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chapnik]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Madar]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Froy]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Biochem Cell Biol]]></source>
<year>2014</year>
<volume>53</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>151-61</page-range></nlm-citation>
</ref>
<ref id="B84">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yvan-Charvet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tall]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>2010</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>139-43</page-range></nlm-citation>
</ref>
<ref id="B85">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adenosine monophosphate activated protein kinase regulates ABCG1-mediated oxysterol efflux from endothelial cells and protects against hypercholesterolemia-induced endothelial dysfunction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>2010</year>
<volume>30</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1354-62</page-range></nlm-citation>
</ref>
<ref id="B86">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cholesterol lowering effect of metformin in combined hyperlipidemia placebo controlled double blind trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pentikainen]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Voutilainen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Aro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Uusitupa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Penttila]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vapaatalo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Med]]></source>
<year>1990</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>307-12</page-range></nlm-citation>
</ref>
<ref id="B87">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diehl]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Fabris]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[De Faria]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Wiechmann]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Carrilho]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<source><![CDATA[AIDS Patient Care STDS]]></source>
<year>2008</year>
<volume>22</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>779-86</page-range></nlm-citation>
</ref>
<ref id="B88">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin prevents the development of chronic heart failure in the SHHF rat model]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cittadini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Napoli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Monti]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Rea]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Longobardi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Netti]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2012</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>944-53</page-range></nlm-citation>
</ref>
<ref id="B89">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes a comparison of patients treated with sulfonylureas and metformin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ogston]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Emslie-Smith]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2006</year>
<volume>49</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>930-6</page-range></nlm-citation>
</ref>
<ref id="B90">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The incidence of congestive heart failure in type 2 diabetes an update]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Gullion]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Koro]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Ephross]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2004</year>
<volume>27</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1879-84</page-range></nlm-citation>
</ref>
<ref id="B91">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The incidence of congestive heart failure associated with antidiabetic therapies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Koro]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Gullion]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Ephross]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Metab Res Rev]]></source>
<year>2005</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>51-7</page-range></nlm-citation>
</ref>
<ref id="B92">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosiak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Postula]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplon-Cieslicka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Trzepla]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Czlonkowski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Filipiak]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Adv Med Sci]]></source>
<year>2013</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>362-8</page-range></nlm-citation>
</ref>
<ref id="B93">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure]]></article-title>
<collab>van der Horst IC.van Melle JP.Qian C.van Gilst WH.Sillje HH</collab>
<source><![CDATA[Am J Physiol Heart Circ Physiol]]></source>
<year>2011</year>
<volume>301</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>H459-68</page-range></nlm-citation>
</ref>
<ref id="B94">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chronic metformin associated cardioprotection against infarction not just a glucose lowering phenomenon]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whittington]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[McLaughlin]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Hausenloy]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yellon]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Mocanu]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiovasc Drugs Ther]]></source>
<year>2013</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-16</page-range></nlm-citation>
</ref>
<ref id="B95">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvert]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Gundewar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Greer]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bestermann]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes]]></source>
<year>2008</year>
<volume>57</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>696-705</page-range></nlm-citation>
</ref>
<ref id="B96">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin mitigates apoptosis in ischemic myocardium]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elmadhun]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
<name>
<surname><![CDATA[Sabe]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Lassaletta]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Sellke]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
</person-group>
<source><![CDATA[J Surg Res]]></source>
<year>2014</year>
<volume>192</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-8</page-range></nlm-citation>
</ref>
<ref id="B97">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lexis]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes the GIPS-III randomized clinical trial]]></article-title>
<collab>van der Horst IC.Lipsic E.Wieringa WG.de Boer RA.van den Heuvel AF</collab>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>311</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1526-35</page-range></nlm-citation>
</ref>
<ref id="B98">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[XZ]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[XJ]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[ZW]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiology]]></source>
<year>2014</year>
<volume>127</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-9</page-range></nlm-citation>
</ref>
<ref id="B99">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treating percutaneous coronary interventionrelated myocardial injury with metformin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvert]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiology]]></source>
<year>2014</year>
<volume>127</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>130-2</page-range></nlm-citation>
</ref>
<ref id="B100">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diabetes and cancer a consensus report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giovannucci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Harlan]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Archer]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Bergenstal]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Gapstur]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Habel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2010</year>
<volume>33</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1674-85</page-range></nlm-citation>
</ref>
<ref id="B101">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus a systematic review and meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barone]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Peairs]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Derr]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>2008</year>
<volume>300</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2754-64</page-range></nlm-citation>
</ref>
<ref id="B102">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status-A prospective study within the EPIC cohort]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaaks]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tikk]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sookthai]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tjonneland]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roswall]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Cancer]]></source>
<year>2014</year>
<volume>134</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2683-90</page-range></nlm-citation>
</ref>
<ref id="B103">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mediation of insulinlike growth factor actions by the insulin receptor in H-35 rat hepatoma cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krett]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Heaton]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Gelehrter]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocrinology]]></source>
<year>1987</year>
<volume>120</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>401-8</page-range></nlm-citation>
</ref>
<ref id="B104">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[On the origin of cancer cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Warburg]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Science]]></source>
<year>1956</year>
<volume>123</volume>
<numero>3191</numero>
<issue>3191</issue>
<page-range>309-14</page-range></nlm-citation>
</ref>
<ref id="B105">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin taking away the candy for cancer?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jalving]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gietema]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lefrandt]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[de Jong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Reyners]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Gans]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Cancer]]></source>
<year>2010</year>
<volume>46</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>2369-80</page-range></nlm-citation>
</ref>
<ref id="B106">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diabetes, cancer, and metformin connections of metabolism and cell proliferation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[LeRoith]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann N Y Acad Sci]]></source>
<year>2011</year>
<volume>1243</volume>
<page-range>54-68</page-range></nlm-citation>
</ref>
<ref id="B107">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Glucoselowering agents and cancer mortality rates in type 2 diabetes assessing effects of time-varying exposure]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bowker]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Yasui]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Veugelers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2010</year>
<volume>53</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1631-7</page-range></nlm-citation>
</ref>
<ref id="B108">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of insulin glargine and cancer incidence in Scotland a study from the Scottish Diabetes Research Network Epidemiology Group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colhoun]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Group]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2009</year>
<volume>52</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1755-65</page-range></nlm-citation>
</ref>
<ref id="B109">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The influence of glucose-lowering therapies on cancer risk in type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Currie]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Poole]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Gale]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>2009</year>
<volume>52</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1766-77</page-range></nlm-citation>
</ref>
<ref id="B110">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New users of metformin are at low risk of incident cancer a cohort study among people with type 2 diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Libby]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Donnelly]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Donnan]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Alessi]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Care]]></source>
<year>2009</year>
<volume>32</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1620-5</page-range></nlm-citation>
</ref>
<ref id="B111">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin and reduced risk of cancer in diabetic patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Donnelly]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Emslie-Smith]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Alessi]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ]]></source>
<year>2005</year>
<volume>330</volume>
<numero>7503</numero>
<issue>7503</issue>
<page-range>1304-5</page-range></nlm-citation>
</ref>
<ref id="B112">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin therapy and risk of cancer in patients with type 2 diabetes systematic review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franciosi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lucisano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lapice]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Strippoli]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Pellegrini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolucci]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>e71583</page-range></nlm-citation>
</ref>
<ref id="B113">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin in cancer therapy a new perspective for an old antidiabetic drug?. Mol Cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ben Sahra]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Le Marchand-Brustel]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tanti]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Bost]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Ther]]></source>
<year>2010</year>
<volume>9</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1092-9</page-range></nlm-citation>
</ref>
<ref id="B114">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin multi-faceted protection against cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Barco]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez-Martin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cufi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveras-Ferraros]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch-Barrera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Joven]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncotarget]]></source>
<year>2011</year>
<volume>2</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>896-917</page-range></nlm-citation>
</ref>
<ref id="B115">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[LKB1 and AMP-activated protein kinase control of mTOR signalling and growth]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Acta Physiol (Oxf)]]></source>
<year>2009</year>
<volume>196</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-80</page-range></nlm-citation>
</ref>
<ref id="B116">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wullschleger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shpiro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McGuire]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Sakamoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Woods]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochem J]]></source>
<year>2008</year>
<volume>412</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>211-21</page-range></nlm-citation>
</ref>
<ref id="B117">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dowling]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Zakikhani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fantus]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Pollak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sonenberg]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res]]></source>
<year>2007</year>
<volume>67</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>10804-12</page-range></nlm-citation>
</ref>
<ref id="B118">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esfahanian]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Shakiba]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nikbin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Soraya]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Maleki-Dizaji]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ghazi-Khansari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Med Rep]]></source>
<year>2012</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1068-74</page-range></nlm-citation>
</ref>
<ref id="B119">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin an emerging new therapeutic option for targeting cancer stem cells and metastasis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rattan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ali Fehmi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Munkarah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[J Oncol]]></source>
<year>2012</year>
<volume>2012</volume>
<page-range>928127</page-range></nlm-citation>
</ref>
<ref id="B120">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin inhibits inflammatory angiogenesis in a murine sponge model]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xavier]]></surname>
<given-names><![CDATA[DO]]></given-names>
</name>
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Cota]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
</person-group>
<source><![CDATA[Biomed Pharmacother]]></source>
<year>2010</year>
<volume>64</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>220-5</page-range></nlm-citation>
</ref>
<ref id="B121">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ersoy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kiyici]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Budak]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Oral]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Guclu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Duran]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2008</year>
<volume>81</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>56-60</page-range></nlm-citation>
</ref>
<ref id="B122">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin a rising star to fight the epithelial mesenchymal transition in oncology]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barriere]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tartary]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rigaud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Anticancer Agents Med Chem]]></source>
<year>2013</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>333-40</page-range></nlm-citation>
</ref>
<ref id="B123">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT) from cancer stem cells to aging-associated fibrosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cufi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez-Martin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveras-Ferraros]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martin-Castillo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Joven]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Menendez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell cycle]]></source>
<year>2010</year>
<volume>9</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>4461-8</page-range></nlm-citation>
</ref>
<ref id="B124">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ben Sahra]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Laurent]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Loubat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Giorgetti-Peraldi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Colosetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Auberger]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncogene]]></source>
<year>2008</year>
<volume>27</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>3576-86</page-range></nlm-citation>
</ref>
<ref id="B125">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ben Sahra]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Regazzetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Robert]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Laurent]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Le MarchandBrustel]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Auberger]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res]]></source>
<year>2011</year>
<volume>71</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>4366-72</page-range></nlm-citation>
</ref>
<ref id="B126">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhuang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Miskimins]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<source><![CDATA[J Mol Signal]]></source>
<year>2008</year>
<volume>3</volume>
<page-range>18</page-range></nlm-citation>
</ref>
<ref id="B127">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dual antiglioma action of metformin cell cycle arrest and mitochondria-dependent apoptosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isakovic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Harhaji]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Stevanovic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Markovic]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[SumaracDumanovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Starcevic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell Mol Life Sci]]></source>
<year>2007</year>
<volume>64</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1290-302</page-range></nlm-citation>
</ref>
<ref id="B128">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin induces unique biological and molecular responses in triple negative breast cancer cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Edgerton]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[XS]]></given-names>
</name>
<name>
<surname><![CDATA[Alimova]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Lind]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell cycle]]></source>
<year>2009</year>
<volume>8</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>2031-40</page-range></nlm-citation>
</ref>
<ref id="B129">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Immune-mediated antitumor effect by type 2 diabetes drug, metformin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eikawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nishida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mizukami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yamazaki]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nakayama]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Udono]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Proc Natl Acad Sci U.S.A]]></source>
<year>2015</year>
<volume>112</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1809-14</page-range></nlm-citation>
</ref>
<ref id="B130">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodwin]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stambolic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Breast]]></source>
<year>2011</year>
<volume>20</volume>
<numero>Suppl 3</numero>
<issue>Suppl 3</issue>
<page-range>S31-5</page-range></nlm-citation>
</ref>
<ref id="B131">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[Mol Cell Biochem]]></source>
<year>2014</year>
<volume>386</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>63-71</page-range></nlm-citation>
</ref>
<ref id="B132">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iliopoulos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Struhl]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res]]></source>
<year>2011</year>
<volume>71</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3196-201</page-range></nlm-citation>
</ref>
<ref id="B133">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Paik]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Cancer]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>170</page-range></nlm-citation>
</ref>
<ref id="B134">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[GZ]]></given-names>
</name>
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Ropelle]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Osorio-Costa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rossato]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Vercesi]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2011</year>
<volume>17</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3993-4005</page-range></nlm-citation>
</ref>
<ref id="B135">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin Association with Lower Prostate Cancer Recurrence in Type 2 Diabetes a Systematic Review and Meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Rieken]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shariat]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
</person-group>
<source><![CDATA[Asian Pac J Cancer Prev]]></source>
<year>2015</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>595-600</page-range></nlm-citation>
</ref>
<ref id="B136">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of metformin on clinical outcomes among men with prostate cancer a systematic review and metaanalysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raval]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Thakker]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vyas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Salkini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Madhavan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sambamoorthi]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<source><![CDATA[Prostate Cancer Prostatic Dis]]></source>
<year>2015</year>
<volume>18</volume>
<page-range>110-21</page-range></nlm-citation>
</ref>
<ref id="B137">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of metformin on cancer risk and treatment outcome of prostate cancer a meta-analysis of epidemiological observational studies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>e116327</page-range></nlm-citation>
</ref>
<ref id="B138">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin and breast cancer risk a meta-analysis and critical literature review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Col]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Ochs]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Springmann]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Aragaki]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Chlebowski]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
</person-group>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2012</year>
<volume>135</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>639-46</page-range></nlm-citation>
</ref>
<ref id="B139">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rego]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Pavan]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Elias]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of metformin on head and neck cancer A systematic review]]></article-title>
<collab>De Luca Canto G.Guerra EN</collab>
<source><![CDATA[Oral Oncol]]></source>
<year>2015</year>
<volume>51</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>416-22</page-range></nlm-citation>
</ref>
<ref id="B140">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin use and lung cancer risk in patients with diabetes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakoda]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Achacoso]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ehrlich]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Quesenberry]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Prev Res (Phila)]]></source>
<year>2015</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>174-9</page-range></nlm-citation>
</ref>
<ref id="B141">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reduced risk of lung cancer with metformin therapy in diabetic patients a systematic review and meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[ZJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Epidemiol]]></source>
<year>2014</year>
<volume>180</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-4</page-range></nlm-citation>
</ref>
<ref id="B142">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus a systematic review and metaanalysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2014</year>
<volume>106</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-26</page-range></nlm-citation>
</ref>
<ref id="B143">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinilla]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<source><![CDATA[Construcción y evaluación de un perfil de competencias profesionales en medicina interna. Colección Desarrollo Humano]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Universidad Nacional de Colombia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B144">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patiño]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<source><![CDATA[Humanismo, medicina y ciencia. En: Silva G (Ed.). Colección Obra Selecta]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Universidad Nacional de Colombia]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
